Together, the combined data obtained from the in vivo models and in vitro experiments suggest a hopeful prospect for using FOXO1 inhibition to restore muscle homeostasis challenged by TDP-43 or FUS LoF, suggesting a potential benefit to reduce muscle wasting in ALS patients. Here, FUS is linked to amyotrophic lateral sclerosis.